Validation of Structured Light Plethysmography - Health and Disease (SLP-RespDis)

PneumaCare

Status: Unknown

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02626468

PMC-T3D-004

Details and patient eligibility

About

Validation of Structured Light Plethysmography (SLP) in patients with conditions such as Chronic Obstructive Pulmonary Disease (COPD) that effect breathing and in healthy participants.

Full description

The investigators hypothesize that SLP may be a useful tool to differentiate between different respiratory diseases. To further examine differences in disease and health, and between diseases SLP measurements will be recorded in a range of diagnostic conditions that effect breathing and in healthy normal subjects.

This is a non-randomised observational study to validate Structured Light Plethysmography in two groups of participants: those with Respiratory condition such as COPD and a normal healthy group. Neither group will receive any clinical intervention. SLP data capture and spirometry (as part of the patients clinical care) will be performed by the patients. The data collected from this study will allow examination of different breathing patterns between patients with different diseases, to compare breathing patterns in patients to those in healthy individuals, and to compare breathing patterns within a healthy population.

Enrollment: 100 estimated patients

Sex: All

Ages: Under 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged between 0 and 80 years

Exclusion criteria

• Any contraindication to spirometry (if performed) or a history of a myocardial infarction or chest surgery within 4 weeks
• Patient unable to sit in an upright (or supine in the case of infants) position for required period of time
• Patients with significant co morbidities (assessed by the clinician at screening only):
• Chest wall or spinal deformity e.g. scoliosis
• Obstructive Sleep Apnoea (OSA) Apnoea hypopnoea index > 30 (if known)
• An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in the study
• BMI > 40
• Inability to consent/comply with trial protocol

Trial design

100 participants in 2 patient groups

Normal

Description:

Participants with no diagnosis of respiratory disease between the ages of 0 and 80

COPD

Description:

Patients from different diagnostic groups between the ages of 0 and 80